BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Knott David M Jr

Knott David M Jr lessened its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 27.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 332,625 shares of the biotechnology company’s stock after selling 127,375 shares during the quarter. BioCryst Pharmaceuticals makes up about 1.4% of Knott David M Jr’s investment portfolio, making the stock its 15th biggest position. Knott David M Jr owned 0.16% of BioCryst Pharmaceuticals worth $2,980,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Allianz Asset Management GmbH lifted its position in BioCryst Pharmaceuticals by 9.6% during the first quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company’s stock worth $103,000 after buying an additional 1,200 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in BioCryst Pharmaceuticals by 7.7% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,992 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 1,288 shares during the period. Royal Bank of Canada lifted its position in BioCryst Pharmaceuticals by 2.4% during the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after buying an additional 1,458 shares in the last quarter. Wellington Management Group LLP grew its stake in BioCryst Pharmaceuticals by 2.6% during the first quarter. Wellington Management Group LLP now owns 91,348 shares of the biotechnology company’s stock worth $685,000 after buying an additional 2,291 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey raised its stake in shares of BioCryst Pharmaceuticals by 8.8% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 49,202 shares of the biotechnology company’s stock valued at $441,000 after acquiring an additional 3,998 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Up 2.6%

BCRX stock opened at $7.08 on Monday. The firm has a 50 day simple moving average of $7.33 and a 200-day simple moving average of $8.63. The company has a market capitalization of $1.49 billion, a P/E ratio of -39.33 and a beta of 1.09. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The business had revenue of $159.40 million for the quarter, compared to analysts’ expectations of $162.91 million. BioCryst Pharmaceuticals’s revenue was up 36.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.07) EPS. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Evercore ISI reiterated an “in-line” rating and issued a $8.00 price target on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. JMP Securities lifted their price objective on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the company a “market outperform” rating in a research note on Wednesday, October 15th. Barclays reduced their target price on shares of BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 4th. Needham & Company LLC lowered their price target on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, November 4th. Finally, Citizens Jmp dropped their price target on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating on the stock in a research note on Wednesday, November 5th. Ten investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $19.33.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.